|
**Overview**: **BOH Advanced Profile****Introduction**: The BOH Advanced Profile is a diagnostic tool designed to screen for recurrent pregnancy loss using serum and whole blood samples. Associated with conditions like antiphospholipid syndrome and thyroid dysfunction, these disorders present with recurrent miscarriages, fatigue, and severe complications if untreated, particularly in individuals with bad obstetric history. Per the 2023 Obstetrics and Gynecology guidelines, the test employs biochemistry, hematology, immunology, and serology with immunoassay and automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for bad obstetric history assessment in clinical settings. This diagnostic falls under recurrent pregnancy loss screening and targets individuals with a history of pregnancy loss, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.**Other Names**: BOH Adv Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, hematology, immunology, and serology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by obstetric labs, this test advanced pregnancy loss diagnostics.**Purpose**: The test screens for 21 parameters including lupus anticoagulant to guide pregnancy loss assessment, assess coagulation and autoimmune status, and inform treatment and prevention strategies.**Test Parameters**: 1. Lupus Anticoagulant, 2. Anticardiolipin IgG, 3. Anticardiolipin IgM, 4. Anti-Beta-2 Glycoprotein IgG, 5. Anti-Beta-2 Glycoprotein IgM, 6. ANA, 7. Anti-dsDNA, 8. TSH, 9. Free T4, 10. Progesterone, 11. Homocysteine, 12. Protein C, 13. Protein S, 14. Antithrombin III, 15. Factor V Leiden, 16. Hemoglobin, 17. RBC Count, 18. Platelet Count, 19. Hematocrit, 20. MCV, 21. Peripheral Smear.**Pretest Condition**: No fasting required; patients should report recurrent miscarriages or recent pregnancy changes.**Specimen**: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 48 hours (Blood) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Blood) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on recurrent miscarriages, fatigue, prior pregnancy complications, or family history of pregnancy disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated pregnancy loss including fetal demise, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and automated cell counter and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent hormone therapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible pregnancy loss causes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early gestation stages.**Specialist Consultation**: General practitioners or specialists in obstetrics or gynecology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Ultrasound or genetic testing for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Obstetrics and Gynecology Guidelines 2023, Journal of Maternal-Fetal Medicine 2024, Biochemistry 2025. |
